Page 133 - 202012

tor receptor-2 inhibitor YN968D1 in patients with ad- 2004，28（10）：451-455.
vanced malignancies[J]. BMC Cancer，2010. DOI：10.1186/ [14] LEE JE，KIM KL，KIM D，et al. Apatinib-loaded nanopar-
1471-2407-10-529. ticles suppress vascular endothelial growth factor-induced
[ 2 ] TIAN S，QUAN HT，XIE CY，et al. YN968D1 is a nov- angiogenesis and experimental corneal neovasculariza-
el and selective inhibitor of vascular endothelial growth tion[J]. Int J Nanomed，2017. DOI：10.2147/IJN.S135133.
factor receptor-2 tyrosine kinase with potent activity in vi- [15] OWEN SC，CHAN DPY，SHOICHET MS，Polymeric mi-
tro and in vivo[J]. Cancer Sci，2011，102（7）：1374-1380. celle stability[J]. Nano Today，2012，7（1）：53-65.
[ 3 ] YANG CX，QIN SK. Apatinib targets both tumor and en- [16] YONCHEVA K，CALLEJA P，AGÜEROS M，et al. Stabi-
dothelial cells in hepatocellular carcinoma[J]. Cancer lized micelles as delivery vehicles for paclitaxel[J]. Int J
Med，2018，7（9）：4570-4583. Pharm，2012，436（1/2）：258-264.
[ 4 ] HAN ZH，HE ZM，WANG CY，et al.The effect of apatinib [17] NEDERBERG F，APPEL E，TAN JPK，et al. Simple ap-
in the treatment of sorafenib resistant metastatic hepatocel- proach to stabilized micelles employing miktoarm terpoly-
lular carcinoma：a case report[J]. Medicine：Baltimore， mers and stereocomplexes with application in paclitaxel
2018. DOI：10.1097/MD.0000000000013388. delivery[J]. Biomacromolecules，2009，10（6）：1460-1468.
[ 5 ] ZHANG L，SHI MQ，HUANG C，et al. A phase Ⅱ，multi- [18] POOL R，BOLHUIS PG，The influence of micelle forma-
center，placebo-controlled trial of apatinib in patients with tion on the stability of colloid surfactant mixtures[J]. Phys
advanced nonsquamous non-small cell lung cancer（NSCLC） Chem Chem Phys，2010，12（44）：14789-14797.
after two previous treatment regimens[J]. J Clin Oncol， [19] DAI YX，WANG S，SHI WB，et al. pH-responsive car-
2012. DOI：10.1200/jco.2012.30.15_suppl.7548. boxymethyl chitosan-derived micelles as apatinib carriers
[ 6 ] HU XC，CAO J，HU WW，et al. Multicenter phase Ⅱ stu- for effective anti-angiogenesis activity：preparation and in
dy of apatinib in non-triple-negative metastatic breast can- vitro evaluation[J]. Carbohydr Polym，2017. DOI：10.1016/
cer[J]. BMC Cancer，2014. DOI：10.1186/1471-2407-14- j.carbpol.2017.08.011.
820. [20] WEI X，LIU LQ，GUO X，et al. Light-activated ROS-re-
[ 7 ] 孙培培，张龙，张泰，等.单药阿帕替尼治疗二线及二线以 sponsive nanoplatformcodelivering apatinib and doxorubi-
上化疗失败的晚期大肠癌患者疗效分析[J].临床肿瘤学 cin forenhanced chemo-photodynamic therapy ofmulti-
杂志，2017，22（7）：646-649. drug-resistant tumors[J]. ACS Appl Mater Inter，2018，10
[ 8 ] QIN SK. Apatinib in Chinese patients with advanced hepa- （21）：17672-17684.
tocellular carcinoma：a phase Ⅱ randomized，open-label [21] DANHIER F，FERON O，PRÉAT V. To exploit the tumor
trial[J]. J Clin Oncol，2014. DOI：10.1200/jco.2014.32.15_ microenvironment：passive and active tumor targeting of
suppl.4019. nanocarriers for anti-cancer drug delivery[J]. J Control Re-
[ 9 ] MI YJ，LIANG YJ，HUANG HB，et al. Apatinib（YN968D1） lease，2010，148（2）：135-146.
reverses multidrug resistance by inhibiting the efflux func- [22] HU YZ，WU C，ZHU CH，et al. Enhanced uptake and im-
tion of multiple ATP-binding cassette transporters[J]. Can- proved anti-tumor efficacy of doxorubicin loaded fibrin
cer Res，2010，70（20）：7981-7991. gel with liposomal apatinib in colorectal cancer[J]. Int J
[10] HALASZ K，KELLY SJ，IQBAL MT，et al. Utilization of Pharm，2018，552（1/2）：319-327.
apatinib-loaded nanoparticles for the treatment of ocular [23] YU T，WU C，ZHU CH，et al. Oral Administration of lipo-
neovascularization[J]. Curr Drug Deliv，2019，16（2）： some-apatinib and locally delivery of docetaxel/MPEG-
153-163. PCL by fibrin glue synergistically improve therapeutic ef-
[11] JEONG JH，NGUYEN HK，LEE JE，et al. Therapeutic ef- fect in colorectal cancer[J]. J Biomed Nanotechnol，2018，
fect of apatinib-loaded nanoparticles ondiabetes-induced 14（12）：2077-2091.
retinal vascular leakage[J]. Int J Nanomed，2016. DOI： [24] SONG ZW，LIN Y，ZHANG X，et al. Cyclic RGD pep-
10.2147/IJN.S108452. tide-modified liposomal drug delivery system for targeted
[12] LI F，LIAO ZC，ZHAO J，et al. Efficacy and safety of apa- oral apatinib administration：enhanced cellular uptake and
tinib in stage Ⅳ sarcomas：experience of a major sarcoma improved therapeutic effects[J]. Int J Nanomed，2017.
center in China[J]. Oncotarget，2017，8（38）：64471- DOI：10.2147/IJN.S125573.
64480. [25] 徐杉，吴敬波，傅少志.水凝胶在抗肿瘤药物中的研究进
[13] 陈莹，平其能.口服载药纳米粒的研究进展[J].药学进展， 展[J].中国现代应用药学，2016，33（5）：676-682.

中国药房 2020年第31卷第12期 China Pharmacy 2020 Vol. 31 No. 12 ·1531 ·